2022 the Japanese Society of Medical Oncology Annual Meeting

Session information

Oral Session

[O10] Oral Session 10 Cross-sectional Program
【E】

Fri. Feb 18, 2022 10:00 AM - 11:30 AM Room 6 (Room D, 1F, Kyoto International Conference Center)

Chair:Maki Tanioka(Clinical AI, Graduate School of Medicine Dentistry and Pharmaceutical Sciences, Oakayama University),Yoichi Naito(Department of General Internal Medicine/Experimental Therapeutics/Medical Oncology, National Cancer Center Hospital East)
Discussant:Yasutoshi Kuboki(Department of Experimental Therapeutics, National Cancer Center Hospital East)

Makoto Tahara1, Marcia S. Brose2, Lin Shen3, Daniel S.W Tan4, Shivaani Kummar5, Jessica J. Lin6,7, Ray Mcdermott8, Jordan Berlin9, Ulrik N. Lassen10, Serge Leyvraz11, Jyoti D. Patel12, Ricarda Norenberg13, Laura Dima14, Nicoletta Brega15, David S. Hong16, Alexander Drilon17,18 (1.Department of Head and Neck Medical Oncology, National Cancer Center Hospital East, 2.Abramson Cancer Center of the University of Pennsylvania School of Medicine, Philadelphia, PA, USA, 3.Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital & Institute, Beijing, China, 4.Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore, 5.Oregon Health & Science University, Portland, OR, USA, 6.Department of Medicine, Massachusetts General Hospital, Boston, MA USA, 7.Harvard Medical School, Boston, MA USA., 8.St Vincent's University Hospital and Cancer Trials Ireland, Dublin, Ireland, 9.Vanderbilt University Medical Center, Nashville, TN, USA, 10.Department of Oncology, Rigshospitalet, Copenhagen, Denmark, 11.Charité – Universitätsmedizin Berlin, Berlin, Germany, 12.Northwestern University, Chicago, IL, USA, 13.Chrestos Concept GmbH & Co. KG, Essen, Germany, 14.Bayer HealthCare Pharmaceuticals, Inc., Basel, Switzerland, 15.Bayer HealthCare Pharmaceuticals, Whippany, NJ, USA, 16.The University of Texas MD Anderson Cancer Center, Houston, TX, USA, 17.Memorial Sloan Kettering Cancer Center, New York, NY, USA, 18.Weill Cornell Medical College, New York, NY, USA)

Melissa Johnson1, Juanita Lopez2, Patricia Lorusso3, Jessica Bauman4, Daniel Haggstrom5, Eleni Lagkadinou6, Gaurav Bajaj7, Ozlem Tureci6, Homer C. Adams Iii7, Ugur Sahin6, Yali Fu7, Tahamtan Ahmadi7, Kristoffer S. Rohrberg8 (1.Sarah Cannon Research Institute, Nashville, TN, USA, 2.Royal Marsden NHS Foundation Trust, Sutton, UK, 3.Yale Cancer Center, New Haven, CT, USA, 4.Fox Chase Cancer Center, Philadelphia, PA, USA, 5.Levine Cancer Institute, Charlotte, NC, USA, 6.BioNTech SE, Mainz, Germany, 7.Genmab, Princeton, NJ, USA, 8.Department of Oncology, Rigshospitalet, University Hospital of Copenhagen, Copenhagen, Denmark)

Hirokazu Ogino1,2, Jennie W Taylor2,3, Takahide Nejo2, David Gibson2, Payal B Watchmaker2, Kaori Okada2, Atsuro Saijo1,2, Meghan Tadesco3, Jane Rabbitt2, Michael R Olin4, Christopher L Moertel4, Andres M Salazar5, Yasuhiko Nishioka1, Annette M Molinaro2,7, Joanna J Phillips2,6, Nicholas A Butowski2, Jennifer L Clarke2, Susan M Chang2, Mitchel Berger2, Hideho Okada2 (1.Department of Respiratory Medicine and Rheumatology, Graduate School of Biomedical Sciences, Tokushima University, 2.Department of Neurological Surgery, University of California, San Francisco, 3.Department of Neurology, University of California, San Francisco, 4.Division of Pediatric Hematology/Oncology, University of Minnesota School of Medicine, 5.Oncovir Inc, 6.Division of Neuropathology, University of California, San Francisco, 7.Department of Epidemiology and Biostatistics, University of California, San Francisco)

Hiroaki Kodama1, Akira Ono1, Toshihiro Takahashi2, Yukihiro Terada2, Takuya Kawata3, Akifumi Notsu4, Keita Mori4, Mitsuhiro Isaka2, Yasuhisa Ohde2, Takashi Nakajima3, Takashi Sugino3, Toshiaki Takahashi1 (1.Division of Thoracic Oncology, Shizuoka Cancer Center, 2.Division of Thoracic Surgery, Shizuoka Cancer Center, 3.Division of Pathology, Shizuoka Cancer Center, 4.Department of Biostatistics, Clinical Research Center, Shizuoka Cancer Center)

Yasutaka Takinishi1, Yoshie Yoshikawa2, Mitsuru Emi1,2, Haining Yang1, Michele Carbone1 (1.Thoracic Oncology, University of Hawaii Cancer Center, 2.Department of Genetic, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan)

Yohei Harada1, Akemi Sato2, Hideaki Nakamura2, Atsujiro Nishioka1, Shinsuke Ogusu1,3, Eisaburo Sueoka2, Masanori Matsumoto4, Atsushi Kawaguchi5, Shinya Kimura1, Naoko Sueoka-Aragane1 (1.Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, 2.Department of Clinical Laboratory Medicine, Faculty of Medicine, Saga University, 3.Department of Thoracic Medical Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, 4.Department of Blood Transfusion Medicine, Nara Medical University, 5.Education and Research Center for Community Medicine, Faculty of Medicine, Saga University)